The nuclear medicine community frequently experiences product shortages. At the time of
this writing, we are
in the midst of a nationwide shortage of Kinevac brand of sincalide injection. Bracco, the manufacturer
Kinevac, is estimating that the shortage may last several months, and there is no other commercially
available source of sincalide (i.e., “generic” version of Kinevac) on the market.
Many of our customers report that they have been approached with offers of “compounded”
from various sources. We at NuTech, Inc. want to bring several issues regarding the use of
compounded sincalide to
your attention to help you make an informed decision regarding these offers.
We at NuTech, Inc. want our patients to receive the very best
quality products available, therefore we have made
the decision to dispense only FDA approved radiopharmaceuticals and adjunct agents. If you are
the use of "compounded" radiopharmaceuticals or adjunct agents in your practice, we suggest that you
the following before making a decision.
Before your facility make the decision to utilize "compounded" radiopharmaceuticals or
agents, take this quiz to help you decide if this
the best decision for your facility and
FDA Approved Radiopharmaceuticals
of commercially radiopharmaceuticals, their approved
manufacturers and their trade names
is available. Nuclear medicine practitioners who receive any of the listed
that originate from sources other than the identified manufacturers may be using unapproved
copies. The list also highlights FDA-approved radiopharmaceuticals that may potentially have
unapproved copies available in the marketplace.